Ibnsina Pharma (CAI:ISPH) Beneish M-Score: -2.45 (As of Jun. 28, 2026)


CAI:ISPH Ibnsina Pharma CAI:ISPH
87 GF Score
Price E£12.05
GF Value E£10.51
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Ibnsina Pharma Beneish M-Score?

Ibnsina Pharma CAI:ISPH -1.23% 87 Beneish M-Score is -2.45 as of Jun. 28, 2026. GuruFocus rates CAI:ISPH with a GF Score™ of 87/100 and a GF Value™ of E£10.51 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 112 Medical Distribution companies, Ibnsina Pharma ranks worse than 52.68% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.45 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Ibnsina Pharma's Beneish M-Score or its related term are showing as below:

CAI:ISPH' s Beneish M-Score Range Over the Past 10 Years
Min: -2.9   Med: -1.89   Max: 12.7
Current: -2.45

During the past 10 years, the highest Beneish M-Score of Ibnsina Pharma was 12.70. The lowest was -2.90. And the median was -1.89.


Ibnsina Pharma Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Ibnsina Pharma's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ibnsina Pharma Beneish M-Score Chart

Ibnsina Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.76 -2.90 -1.49 -1.74 -2.08

Ibnsina Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.60 -1.47 -1.68 -2.08 -2.45

CAI:ISPH vs MCK, COR, CAH: Beneish M-Score Comparison

For the Medical Distribution subindustry, Ibnsina Pharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ibnsina Pharma Beneish M-Score vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Ibnsina Pharma's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Ibnsina Pharma's Beneish M-Score falls into.


CAI:ISPH
87GF Score
Ibnsina Pharma CAI:ISPH
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ibnsina Pharma Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Ibnsina Pharma for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9338+0.528 * 0.973+0.404 * 1.0134+0.892 * 1.2847+0.115 * 0.9655
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.2537+4.679 * -0.022759-0.327 * 0.9925
=-2.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was E£22,863 Mil.
Revenue was 20500.934 + 21202.939 + 20348.859 + 18000.298 = E£80,053 Mil.
Gross Profit was 1639.564 + 1708.648 + 1691.981 + 1621.125 = E£6,661 Mil.
Total Current Assets was E£35,181 Mil.
Total Assets was E£39,167 Mil.
Property, Plant and Equipment(Net PPE) was E£3,342 Mil.
Depreciation, Depletion and Amortization(DDA) was E£362 Mil.
Selling, General, & Admin. Expense(SGA) was E£434 Mil.
Total Current Liabilities was E£34,246 Mil.
Long-Term Debt & Capital Lease Obligation was E£2,039 Mil.
Net Income was 255.936 + 292.139 + 271.037 + 206.927 = E£1,026 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = E£0 Mil.
Cash Flow from Operations was 476.687 + 1687.609 + 889.815 + -1136.67 = E£1,917 Mil.
Total Receivables was E£19,058 Mil.
Revenue was 17044.961 + 17440.824 + 15588.14 + 12237.828 = E£62,312 Mil.
Gross Profit was 1427.622 + 1390.386 + 1194.084 + 1032.98 = E£5,045 Mil.
Total Current Assets was E£29,430 Mil.
Total Assets was E£32,691 Mil.
Property, Plant and Equipment(Net PPE) was E£2,731 Mil.
Depreciation, Depletion and Amortization(DDA) was E£285 Mil.
Selling, General, & Admin. Expense(SGA) was E£269 Mil.
Total Current Liabilities was E£29,342 Mil.
Long-Term Debt & Capital Lease Obligation was E£1,172 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(22863.32 / 80053.03) / (19057.964 / 62311.753)
=0.285602 / 0.305849
=0.9338

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(5045.072 / 62311.753) / (6661.318 / 80053.03)
=0.080965 / 0.083211
=0.973

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (35180.975 + 3342.355) / 39166.759) / (1 - (29429.971 + 2731.324) / 32691.248)
=0.016428 / 0.016211
=1.0134

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=80053.03 / 62311.753
=1.2847

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(284.504 / (284.504 + 2731.324)) / (361.943 / (361.943 + 3342.355))
=0.094337 / 0.097709
=0.9655

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(433.568 / 80053.03) / (269.185 / 62311.753)
=0.005416 / 0.00432
=1.2537

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2039.215 + 34245.628) / 39166.759) / ((1171.672 + 29342.278) / 32691.248)
=0.926419 / 0.933398
=0.9925

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(1026.039 - 0 - 1917.441) / 39166.759
=-0.022759

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Ibnsina Pharma has a M-score of -2.45 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.45 mean?
Ibnsina Pharma (CAI:ISPH) has a Beneish M-Score of -2.45 as of Jun. 28, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Ibnsina Pharma and its competitors. According to the industry distribution chart, Ibnsina Pharma ranks #59 out of 112 companies in the Medical Distribution industry, placing it in the top 52.7%.
Is Ibnsina Pharma's Beneish M-Score too high?
Ibnsina Pharma's current Beneish M-Score is -2.45. Based on the distribution chart, Ibnsina Pharma ranks #59 out of 112 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Ibnsina Pharma has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ibnsina Pharma's Beneish M-Score compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Ibnsina Pharma ranks #59 out of 112 companies for Beneish M-Score. This places Ibnsina Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Distribution company?
A good Beneish M-Score depends on the Medical Distribution industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Ibnsina Pharma and its competitors. Ibnsina Pharma's current Beneish M-Score is -2.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ibnsina Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ibnsina Pharma (CAI:ISPH) is currently considered Modestly Overvalued. The stock's GF Value™ is E£10.51, compared to a current price of E£12.05 — trading 14.7% above its estimated fair value. The current Beneish M-Score is -2.45. Ibnsina Pharma's overall GF Score™ is 87/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Ibnsina Pharma (CAI:ISPH), the current Beneish M-Score is -2.45 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ibnsina Pharma (CAI:ISPH) Overvalued in 2026?

Based on GuruFocus' analysis, Ibnsina Pharma stock appears to be overvalued. The current stock price of E£12.05 is trading 14.7% above its estimated GF Value™ of E£10.51. GuruFocus considers Ibnsina Pharma to be Modestly Overvalued.

Key valuation signals for CAI:ISPH:

  • Beneish M-Score: -2.45
  • GF Value™: E£10.51 vs. price of E£12.05 (14.7% above fair value)
  • GF Score™: 87/100 with 7 warning signs

No single metric tells the full story. See the CAI:ISPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ibnsina Pharma Business Description

Address Industrial zone 1, PO box 91, Obour, EGY
Ibnsina Pharma is an Egypt-based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical, and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, packaging, market research, and analysis.
87GF Score

Get the complete analysis for CAI:ISPH

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£12.05
Price
E£10.51
GF Value